Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Diabetes

Diabetes

Subtypes of Diabetes

Type 2 Diabetes 313 Type 1 Diabetes 57 Prediabetes 31 Diabetic Macular Edema 17 Diabetic Nephropathy 12 Diabetic Peripheral Neuropathy 11 Diabetic Ketoacidosis 9 Diabetic neuropathy 4 Hypoglycemia 4 Diabetic Foot Osteomyelitis 3 Proliferative diabetic retinopathy 3 Type 3c Diabetes 3 Glycemic Control 2 New-Onset Diabetes 2 Post-transplant diabetes mellitus 2 Diabetic emergencies 1 Diabetic osteoporosis 1 Diabetic Wound Healing 1 Glycemic management 1 Hyperglycemia in pregnancy 1 Hyperglycemic Crisis 1 Hyperosmolar hyperglycemic state 1 Impaired Awareness of Hypoglycemia 1 Insulin-Dependent Diabetes 1 Non-proliferative diabetic retinopathy 1 Normal Hypoglycemia Awareness 1 Painful diabetic peripheral neuropathy 1 Plantar Diabetic Foot Ulcers 1 Postprandial Hyperglycemia 1 Steroid-induced diabetes 1 Steroid-induced hyperglycemia 1 Type 2 Diabetes Mellitus with Mild Cognitive Impairment 1 Type 3 Diabetes Mellitus 1 Diabetic Retinal Disease 0 Diabetic sensorimotor polyneuropathy 0 Hemichorea associated with non-ketotic hyperglycemia 0

624 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Diabetes

750 trials tracked for Diabetes: 270 in phase 3 or 4 and 101 with published results. The most-cited published study has 7588 citations.

750Trials tracked
270Phase 3 & 4
0Recruiting
101With published results
Phase distribution
Phase 4 86 Phase 3 184 Phase 2 59 Phase 1 21 Other / NA 400
  1. Phase 3 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Completed · 7,588 cited
  2. Phase 3 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes Completed · 6,872 cited
  3. Phase 3 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Completed · 1,986 cited
  4. Phase 4 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus Completed · 1,822 cited
  5. Phase 3 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Completed · 790 cited
  6. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes Completed · 742 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Completed · 594 cited
  2. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Completed · 592 cited
  3. Phase 3 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Completed · 574 cited
  4. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes Completed · 495 cited
  5. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Completed · 492 cited
  6. Phase 3 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes Completed · 464 cited
  7. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Completed · 461 cited
  8. Phase 3 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Completed · 419 cited
  9. Phase 3 Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Completed · 417 cited
  10. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Completed · 411 cited
  11. Phase 3 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Completed · 410 cited
  12. Phase 3 Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Completed · 400 cited
  13. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Completed · 375 cited
  14. Phase 3 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed · 367 cited
  15. Phase 3 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes Completed · 358 cited
  16. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment Completed · 349 cited
  17. Phase 3 The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes Completed · 345 cited
  18. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed · 299 cited
  19. Phase 3 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes Completed · 298 cited
  20. Phase 4 Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI Completed · 287 cited
  21. Phase 3 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Completed · 285 cited
  22. Phase 3 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Completed · 262 cited
  23. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes Completed · 256 cited
  24. Phase 4 Stop Atherosclerosis in Native Diabetics Study Completed · 245 cited
  25. Phase 3 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Completed · 226 cited
  26. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes Completed · 222 cited
  27. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Completed · 220 cited
  28. Phase 3 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Completed · 210 cited
  29. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes Completed · 206 cited
  30. Phase 3 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus Completed · 194 cited
  31. Phase 4 Reducing Total Cardiovascular Risk in an Urban Community Completed · 187 cited
  32. Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes Completed · 178 cited
  33. Phase 4 Effect of Testosterone in Men With Erectile Dysfunction Completed · 163 cited
  34. Phase 3 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy Completed · 136 cited
  35. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Completed · 132 cited
  36. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes Completed · 126 cited
  37. Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Completed · 120 cited
  38. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) Completed · 111 cited
  39. Phase 3 Insulin Resistance Intervention After Stroke Trial Completed · 109 cited
  40. Phase 3 The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy Completed · 109 cited
  41. Phase 4 Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life. Completed · 100 cited
  42. Phase 4 Acute Effect of Exenatide on Brain Glucose Metabolism Completed · 95 cited
  43. Phase 3 RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects Completed · 92 cited
  44. Phase 3 Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes Completed · 80 cited

Showing the 50 most-cited and recently-updated of 750 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Diabetes: what the trials found

Albiglutide 30 mg was associated with significant differences in the time to first occurrence of Major Adverse Cardiovascular Events (MACE) during cardiovascular follow-up 17 and for MACE or urgent revascularization for unstable angina 17. However, no significant difference was found in the time to adjudicated CV death 17.

The use of antiplatelet agents was associated with a reduction in low-density lipoprotein cholesterol 20, a decrease in systolic blood pressure 20, and a statistically significant change in HbA1c levels 20.

Sildenafil citrate (open label) was associated with improvements in the Erectile Function Domain Score of the International Index of Erectile Function (IIEF) 21, as well as changes in the Psychological General Well-Being Index Score (PGWBI) 21 and the Positive Affects Ratio (PAR) 21.

Recent results — preliminary, needs further review

  • Ertugliflozin 15 mg was evaluated for its effect on blood pressure, with results showing significant values across multiple measurements 1.
  • The DASH4D diet was associated with specific Systolic Blood Pressure (SBP) outcomes 4.
  • Smart insulin pens and CGM were associated with a decrease in HbA1c percentage, an increase in the percentage of glucose values in range, and a negligible change in the percentage of glucose values below range 12.
  • The SDH Tool was associated with various DM Key Test outcomes 14.
  • Other interventions under investigation or recently studied include standard of care insoles 2, VasQ 3, surgical procedures like Carotid Endarterectomy 9, and various programs such as the Diabetes Prevention Program 6, Culinary Medicine Program 10, and Family Check Up Heart 15.

For the clinician treating this condition

  • Albiglutide 30 mg demonstrated significant impacts on MACE timelines in patients with cardiovascular follow-up, though it did not significantly affect CV death rates.
  • Antiplatelet agents showed multi-faceted benefits including improvements in lipid profiles, blood pressure, and HbA1c levels.
  • Technological interventions like smart insulin pens combined with CGM were associated with improved glycemic control (HbA1c) and increased time-in-range.

AI synthesis of 13 cited trials, updated Jun 19, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Diabetes: current evidence & treatments

Diabetes mellitus is associated with a high burden of microvascular and macrovascular complications, including diabetic neuropathy, retinopathy, nephropathy, and peripheral arterial disease, as observed in adult Ugandans 2. Chronic hyperglycemia contributes to multi-level nerve damage across peripheral, autonomic, and central nervous systems, driven by metabolic and vascular disturbances such as oxidative stress and microvascular dysfunction 6. Immunometabolic dysregulation, including activation of the polyol pathway, advanced glycation end products, and mitochondrial dysfunction, creates a pro-inflammatory microenvironment that drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy 1.

Pharmacological interventions show varying benefits in diabetes management. Semaglutide reduces the risk of kidney decline or death in type 2 diabetes with chronic kidney disease 10 and improves metabolic health in schizophrenia patients on antipsychotics 15. GLP-1 receptor agonists may reduce cognitive decline in type 2 diabetes patients with dementia 13 and are associated with a lower risk of serious liver events compared with DPP-4 inhibitors 25. SGLT2 inhibitors are associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes 3. Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis 16. Metformin is associated with higher lactate concentrations during exercise in adults with prediabetes and type 2 diabetes 8. Insulin degludec/liraglutide ranks highest for HbA1c reduction among fixed-ratio combinations 20. Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in diabetic macular edema 9.

Emerging technologies and genetic insights are advancing diabetes care. Transcriptomic analysis identified 337 high-confidence type 2 diabetes-associated genes in human pancreatic islets, with an IsletDysfunctionScore showing significant separation between non-diabetic and type 2 diabetes islets 5. AI-driven cardiovascular risk prediction in type 2 diabetes shows promise but is limited by bias and lack of diversity 23. Pancreatic tissue engineering for type 1 diabetes faces a vascularization hurdle 7. CAR technology is being explored for type 1 diabetes among other conditions 11. scFv-based biologics show potential for immunomodulation in both type 1 and type 2 diabetes 19. Adipose-derived stem cell exosomes are being investigated for diabetic foot ulcers, but efficacy data are lacking 14.

Key drugs in the evidence

metformin 8 SGLT2 inhibitors 6 sodium-glucose cotransporter 2 inhibitors 4 aspirin 3 glucagon-like peptide-1 receptor agonists 3 GLP-1 receptor agonists 3 statins 3 insulin 3 semaglutide 3 prasugrel 2

Latest findings

AI-generated synthesis of 17 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Indole-AhR-Treg axis proposed as context-dependent target for restoring tolerance in type 1 diabetes
Diabetes & Endocrinology Sys. Review
Indole-AhR-Treg axis proposed as context-dependent target for restoring tolerance in type 1 diabetes Gut Metabolites May Help Explain Type 1 Diabetes Immune Attack
This narrative review synthesizes mechanistic and translational evidence on microbiome-derived tryptophan indole metabolites (IAA, ICA, IPA)…
Gut bacteria make molecules that may calm the immune attack in type 1 diabetes. A new review explains how this could work, but human proof i…
Frontiers Oct 31, 2026
Older age correlates with higher hearing-related symptom scores in adults with diabetes
ENT (Otolaryngology) Sys. Review
Older age correlates with higher hearing-related symptom scores in adults with diabetes Older Age Tied to More Hearing Symptoms in Diabetes
This cross-sectional study of 128 adults with diabetes found that older age is associated with higher hearing-related symptom scores. Sex wa…
In adults with diabetes, older age and being female were linked to more self-reported hearing symptoms, but the study cannot show cause.
Frontiers Oct 30, 2026
Anti-inflammatory strategies may stabilize mental functioning and promote autonomic and metabolic homeostasis
Diabetes & Endocrinology Sys. Review
Anti-inflammatory strategies may stabilize mental functioning and promote autonomic and metabolic homeostasis Inflammation and Nerve Imbalance Linked to Anxiety and Metabolic Ills
This narrative review explores the roles of metainflammation, autonomic instability, and anti-inflammatory strategies in anxiety and cardiom…
A new review links chronic inflammation and unstable nerve signals to anxiety, obesity, and diabetes, but it is early, broad thinking, not p…
Frontiers Oct 30, 2026
Digital phenotyping enables real-time mental health monitoring and risk prediction in people with diabetes
Psychiatry Sys. Review
Digital phenotyping enables real-time mental health monitoring and risk prediction in people with diabetes Digital Tools May Help Track Mental Health in People with Diabetes
This scoping review of 10 studies examines the use of digital phenotyping, including CGM and smartphone sensing, for mental health monitorin…
New digital tools like smartphone sensors and glucose monitors may help track and predict mental health issues in people living with diabete…
Frontiers Oct 29, 2026
Autoimmune comorbidities recur with MS, but evidence cannot define a prodrome or distinct subgroups
Neurology Sys. Review
Autoimmune comorbidities recur with MS, but evidence cannot define a prodrome or distinct subgroups Common autoimmune conditions often occur alongside multiple sclerosis
This scoping review synthesizes evidence on immune-mediated comorbidities in multiple sclerosis. Autoimmune thyroid disease, type 1 diabetes…
People with multiple sclerosis often have other autoimmune conditions like thyroid disease or psoriasis, but the link to disease progression…
Frontiers Oct 29, 2026
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing
Cardiology Meta-analysis
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing New Prediction Models Help Identify Heart Failure Risk in Diabetes
This meta-analysis of 65 studies evaluated prediction models for incident heart failure and heart failure hospitalization in people with typ…
New prediction models show promise in identifying heart failure risks for people living with type 2 diabetes.
Oct 29, 2026
Genome-wide meta-analysis identifies 25 trait-loci associations for cardiometabolic phenotypes in Native Hawaiian and Samoan populations
Diabetes & Endocrinology Meta-analysis
Genome-wide meta-analysis identifies 25 trait-loci associations for cardiometabolic phenotypes in Native Hawaiian and Samoan populations Native Hawaiian and Samoan DNA study finds new genetic links to diabetes risk
This meta-analysis of a genome-wide association study identifies 25 trait-loci associations for 13 adiposity and cardiometabolic traits in a…
A DNA study of 8,461 Native Hawaiians and Samoans found 25 genetic links to traits like blood sugar and body fat, including 5 that may be ne…
Oct 27, 2026
Adipo-B correlates with beta-cell indices in treatment-naive patients with Type 2 Diabetes
Diabetes & Endocrinology RCT
Adipo-B correlates with beta-cell indices in treatment-naive patients with Type 2 Diabetes New marker may help track insulin production in Type 2 Diabetes
This prospective, non-randomized observational study of 253 treatment-naive patients with Type 2 Diabetes found that adipo-B levels correlat…
A new protein marker could offer a simple way for doctors to track how well the body produces insulin in people with Type 2 Diabetes.
medRxiv Oct 27, 2026
Telemedicine for gestational diabetes reduces fasting glucose and gestational weight gain in women
Diabetes & Endocrinology Meta-analysis
Telemedicine for gestational diabetes reduces fasting glucose and gestational weight gain in women Telemedicine Shows Potential for Managing Gestational Diabetes Care
This meta-analysis of 3055 women with gestational diabetes found that telemedicine interventions associated with lower fasting glucose (MD -…
Telemedicine may help manage blood sugar and weight gain in pregnant women with gestational diabetes, though the evidence is currently limit…
Oct 24, 2026
Unhealthy food environments and ultra-processed foods contribute to obesity and related cardiometabolic diseases
Nutrition & Obesity Medicine Sys. Review
Unhealthy food environments and ultra-processed foods contribute to obesity and related cardiometabolic diseases Food Environments Linked to Obesity and Type 2 Diabetes
This narrative review examines how food environment factors like accessibility and affordability influence the consumption of ultra-processe…
Unhealthy food environments and ultra-processed foods are linked to serious conditions like insulin resistance, heart disease, and chronic k…
Frontiers Oct 23, 2026
High prevalence of vitamin B12 deficiency in South Asian pregnant women suggests risk for adverse outcomes
Nutrition & Obesity Medicine Sys. Review
High prevalence of vitamin B12 deficiency in South Asian pregnant women suggests risk for adverse outcomes Vitamin B12 deficiency is common among pregnant women in South Asia
This narrative review examines the prevalence of vitamin B12 deficiency in pregnant women in South Asia and its association with maternal an…
Up to 70% of pregnant women in South Asia may have low vitamin B12, a finding that could impact both mother and baby health.
Frontiers Oct 23, 2026
Retatrutide Shifts Fatty Acid Oxidation and Insulin Resistance Metabolites in Obesity Trials
Diabetes & Endocrinology RCT
Retatrutide Shifts Fatty Acid Oxidation and Insulin Resistance Metabolites in Obesity Trials New drug retatrutide shows promise for weight loss and diabetes
In phase 2 trials, retatrutide altered two metabolite clusters tied to fatty acid oxidation and insulin resistance, with ketone and acylcarn…
A new medication called retatrutide may help manage weight and insulin resistance by changing specific markers in the blood for people with …
Oct 22, 2026

Questions about Diabetes

How many pregnant women were in the Lp(a) gestational diabetes risk study?

The Lp(a) gestational diabetes risk study included 922 pregnant women with normal glucose tolerance (NGT) after propensity score matching.

Full answer →
What is the link between diabetes and the immune system fighting tuberculosis?

Diabetes weakens the immune system's ability to control tuberculosis, increasing risk of infection and worse outcomes.

Full answer →
Can surgery help heal wounds caused by gouty tophi in patients with diabetes?

Yes, surgery can help heal wounds from gouty tophi, but diabetes increases the risk of delayed healing and infection, so careful preoperative management is essential.

Full answer →
How does having diabetes affect the risk of infection after spinal surgery?

Yes, diabetes significantly increases the risk of infection after spinal surgery, with studies showing roughly 3-4 times higher odds of surgical site infection.

Full answer →
Can immune checkpoint inhibitors cause diabetes mellitus in patients?

Yes, immune checkpoint inhibitors can cause diabetes mellitus, often presenting suddenly with diabetic ketoacidosis.

Full answer →
Do voltage-dependent potassium channels play a role in diabetes research findings?

Yes, voltage-dependent potassium (Kv) channels help regulate insulin secretion, and their dysfunction is linked to diabetes. Research explores them as potential drug targets.

Full answer →
Does switching to integrase inhibitors increase the risk of developing diabetes in HIV patients?

Yes, switching to integrase inhibitors (INSTIs) is linked to an increased risk of developing diabetes in people with HIV, based on recent studies.

Full answer →
Can Ganoderma lucidum polysaccharides help manage diabetes and related complications?

Yes, Ganoderma lucidum polysaccharides (GLPs) show potential to help manage diabetes and its complications through antioxidant, anti-inflammatory, and blood sugar-lowering effects, but human trials are needed.

Full answer →
See all 8 questions about Diabetes →

All Diabetes Articles